Abstract: Provided is a method for the high expression of a recombinant human serum albumin, characterized in comprising the step of co-expressing: (a) a human serum albumin gene, and (b) one or more rHSA expression promoting factor genes in a yeast host cell.
Type:
Grant
Filed:
May 4, 2017
Date of Patent:
October 28, 2025
Assignee:
Shenzhen Protgen Ltd.
Inventors:
Guodong Chang, Xin Dou, Xiaobo Xiong, Wenchao Wang
Abstract: Provided is the use of human serum albumin in the manufacturing of a drug for treating diabetes, obesity, atherosclerosis, Alzheimer's disease, Parkinson's disease and other diseases. In a preferred embodiment, the human serum albumin is the recombinantly prepared young and uninjured human serum albumin, and has achieved excellent effects in reducing the blood sugar level of a diabetic patient.
Type:
Application
Filed:
November 1, 2021
Publication date:
December 7, 2023
Applicant:
Shenzhen Protgen Ltd.
Inventors:
Yongzhang Luo, Yan Fu, Hongyi Liu, Anji Ju, Jiaze Tang, Yi Jiang, Boyuan Ma, Xiaoqin Jiang, Yu Feng, Guodong Chang, Hui Li
Abstract: Provided is a method for the high expression of a recombinant human serum albumin, characterized in comprising the step of co-expressing: (a) a human serum albumin gene, and (b) one or more rHSA expression promoting factor genes in a yeast host cell.
Type:
Application
Filed:
May 4, 2017
Publication date:
October 31, 2019
Applicant:
Shenzhen Protgen Ltd.
Inventors:
Guodong Chang, Xin Dou, Xiaobo Xiong, Wenchao Wang
© 2026 Justia
